Alliance Wealth Advisors LLC UT Cuts Position in Medtronic PLC $MDT

Key Points

• Alliance Wealth Advisors LLC UT cut its Medtronic stake by 32.7%, selling 15,236 shares and leaving it with 31,303 shares valued at about $3.01 million per the latest 13F filing.
• Insider sale: EVP Harry Skip Kiil sold 52,524 shares for roughly $5.13 million (a 61.6% reduction), leaving him with 32,768 shares, and corporate insiders now own about 0.26% of the company.
• Analyst and company outlook: Several brokers trimmed price targets but the consensus is a "Moderate Buy" with an average target of $107.80; Medtronic beat quarterly EPS and revenue, set FY26 EPS guidance of $5.62–$5.66, and pays a $2.84 annual dividend (3.6% yield).

Alliance Wealth Advisors LLC UT decreased its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 32.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 31,303 shares of the medical technology company's stock after selling 15,236 shares during the period. Alliance Wealth Advisors LLC UT's holdings in Medtronic were worth $3,007,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in MDT. Vanguard Group Inc. grew its position in Medtronic by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company's stock valued at $12,388,027,000 after purchasing an additional 1,888,381 shares during the last quarter. State Street Corp raised its holdings in Medtronic by 1.0% in the third quarter. State Street Corp now owns 60,460,537 shares of the medical technology company's stock worth $5,800,550,000 after buying an additional 625,992 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Medtronic by 0.9% in the third quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company's stock worth $2,044,637,000 after buying an additional 192,410 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Medtronic by 0.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company's stock worth $2,008,278,000 after buying an additional 98,220 shares in the last quarter. Finally, Raymond James Financial Inc. grew its holdings in shares of Medtronic by 3.0% during the third quarter. Raymond James Financial Inc. now owns 11,203,865 shares of the medical technology company's stock valued at $1,067,055,000 after buying an additional 327,899 shares during the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. UBS Group reduced their price target on shares of Medtronic from $104.00 to $90.00 and set a "neutral" rating for the company in a research report on Wednesday, April 22nd. Citigroup cut their target price on Medtronic from $117.00 to $110.00 and set a "buy" rating on the stock in a research note on Tuesday, April 7th. JPMorgan Chase & Co. reduced their target price on Medtronic from $105.00 to $100.00 and set a "neutral" rating for the company in a report on Wednesday, February 18th. Daiwa Securities Group decreased their price target on Medtronic from $117.00 to $115.00 and set a "buy" rating for the company in a research note on Friday, February 27th. Finally, Robert W. Baird upped their price target on Medtronic from $92.00 to $93.00 and gave the company a "neutral" rating in a report on Wednesday, April 15th. Fifteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $107.80.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the firm's stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.26% of the company's stock.

Medtronic Trading Down 2.1%

Shares of MDT stock opened at $78.33 on Tuesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The company has a market cap of $100.56 billion, a price-to-earnings ratio of 21.82, a PEG ratio of 1.90 and a beta of 0.62. Medtronic PLC has a 1 year low of $78.29 and a 1 year high of $106.33. The firm has a fifty day moving average price of $88.44 and a 200-day moving average price of $94.80.

Medtronic (NYSE:MDT - Get Free Report) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company had revenue of $9.02 billion for the quarter, compared to analysts' expectations of $8.89 billion. During the same period last year, the firm earned $1.38 EPS. Medtronic's revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.57 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were paid a dividend of $0.71 per share. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.6%. Medtronic's payout ratio is 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.